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Abstract 
One essential component in the construction of patent landscapes in biomedical research and 
development (R&D) is identifying the most seminal patents. Hitherto, the identification of 
seminal patents required subject matter experts within biomedical areas. In this brief 
communication, we report an analytical method and tool, Patent Citation Spectroscopy (PCS), 
for rapidly identifying landmark patents in user-specified areas of biomedical innovation. PCS 
mines the cited references within large sets of patents and provides an estimate of the most 
historically impactful prior work. The efficacy of PCS is shown in two case studies of biomedical 
innovation with clinical relevance: (1) RNA interference and (2) cholesterol. PCS mined and 
analyzed 4,065 cited references related to patents on RNA interference and correctly identified 
the foundational patent of this technology, as independently reported by subject matter experts 
on RNAi intellectual property. Secondly, PCS was applied to a broad set of patents dealing with 
cholesterol – a case study chosen to reflect a more general, as opposed to expert, patent 
search query. PCS mined through 11,326 cited references and identified the seminal patent as 
that for Lipitor, the groundbreaking medication for treating high cholesterol as well as the pair of 
patents underlying Repatha. These cases suggest that PCS provides a useful method for 
identifying seminal patents in areas of biomedical innovation and therapeutics. The interactive 
tool is free-to-use at: www.leydesdorff.net/pcs/. 
 
 
                                                 
1 *corresponding author; Social and Behavioral Sciences Department, The MITRE Corporation, McLean, 
VA, United States; jcomins@gmail.com  
‡ The author's affiliation with The MITRE Corporation is provided for identification purposes only, and is 
not intended to convey or imply MITRE's concurrence with, or support for, the positions, opinions or 
viewpoints expressed by the author. Approved for Public Release; Distribution Unlimited Case #17-0951. 
2 National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, 21224  
3 Amsterdam School of Communication Research (ASCoR), University of Amsterdam, PO Box 15793, 
1001 NG Amsterdam, The Netherlands  
  Page 2 of 14 
Introduction 
Amongst the various components of a patent landscape, identifying seminal patents in an 
innovation area requires substantial investment from specialists (e.g., Schmidt, 2007). Hitherto, , 
subject matter experts review a large corpus of patents and patent applications within their 
historical context to render a judgment of the most technologically important patents. This 
method is time-consuming, difficult to replicate, and predicated on the availability of subject 
matter experts (Cockburn et al., 2002) – and yet, there is a requirement for patent examiners 
and historians of science. Thus, there is a need for automated methods for uncovering insights 
about landmark patents in technology areas (Jensen and Murray, 2005; Konski and 
Spielthenner, 2009).  
Clinical advances depend upon a sound understanding of biomedical research and 
development. The importance of maintaining situational awareness of biomedical R&D activities 
for businesses and policy-makers is best exemplified by the proliferation of patent landscapes 
produced by subject matter experts covering a wide range of topics  (e.g., CRISPR: Egelie et al, 
2016; Induced Pluripotent Stem Cells: Roberts et al, 2014, Bergman & Graff, 2007; Prenatal 
Testing: Agarwal et al., 2013; Carbon Nanotubes: Harris and Bawa, 2007; Nanomedicine: 
Wagner et al, 2006; Gene Sequences: Jensen & Murray, 2005). Given the enormous growth in 
the number of annual patent applications filed (USPTO, 2016), particularly in the life and 
biomedical sciences (Moses et al., 2015), there is increasing demand for patent landscapes 
across a panoply of technologies. In light of this growing need, we introduce an algorithmic 
approach and web-application for identifying landmark patents, a key component of patent 
landscapes, across user-specific biomedical areas. 
Patent Citation Spectroscopy (PCS) operates over the cited references of large sets of 
patents to determine the seminal prior works within a given field, as well as an openly available 
web-application for performing PCS. In this brief communication, we apply PCS to two areas of 
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biomedical innovation: (1) RNA interference and (2) cholesterol. RNAi was selected to examine 
the efficacy of PCS for understanding the origins of an emerging technology with well-
documented expert reviews to ground our findings (Schmidt, 2007). Cholesterol was selected to 
consider how PCS performs for searches on broad areas of biomedical innovation and clinical 
relevance that reflect the less sophisticated kind of searches conducted by users that are not 
library scientists or patent experts. 
Methods  
PCS Algorithm  
PCS can be performed over a set of US patent data that includes a list of referenced patents, or 
backward citations. Our study utilizes data from PatentsView, a data platform sponsored by the 
USPTO. PatentsView provides backward citation information for all US patents from 1976 
through July 2016 via an Application Program Interface (API). We leverage this API both in 
demonstrating the utility of PCS to identify seminal patents and in creating a tool that makes 
PCS widely available for further use. 
The core set of computations performed by PCS are largely consistent with that of the 
Reference Publication Year Spectroscopy (RPYS) technique (Marx et al., 2014), with one 
notable exception: the normalization is different. Briefly, RPYS aggregates the references within 
documents and organizes those references by their publication date. Once organized, these 
values are summed so that each reference publication year represents the cumulative number 
of references it received from the citing set of documents. Then, for each reference publication 
year, the absolute deviation between the focal year and the median number of references for 
the five-year period that includes the focal year is calculated. The resulting vector is traditionally 
graphed as a line. Viewing the line, analysts then search for maxima, or peaks, as indicators of 
seminal works being published in a given year. Thus far, RPYS has successfully been used to 
identify seminal research publications across a multitude of scientific domains (Comins and 
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Hussey 2015a; Elango et al. 2016; Leydesdorff et al. 2016; Leydesdorff et al. 2014; Marx and 
Bornmann 2013; Marx et al. 2014; Thor et al. 2016; Wray and Bornmann 2014; Comins and 
Hussey 2015b; Comins and Leydesdorff 2016). In addition, recent work shows the convergence 
between RPYS and subject matter expert’s identification of seminal scientific papers within 
given areas of basic biomedical research (Comins & Leydesdorff, 2017).  
Returning to the case of PCS, the relevant patents are first retrieved from the PatentsView API. 
Next, the cited patent references within each patent of this relevant result set are extracted and 
organized by the year those references were granted. We then sum the number of references 
attributed to each year. These data are de-trended by taking the absolute deviation of the 
number of cited references for a given reference year from the 5-year median of patent 
references. This is represented by the equation: 
 𝑓(𝑡) =   𝐶𝑡 −  𝑀𝑑(𝐶𝑡−2, 𝐶𝑡−1, 𝐶𝑡, 𝐶𝑡+1, 𝐶𝑡+2)  (1) 
where C represents the total sum of citations to patents granted in year t and Md represents the 
median. These first steps mirror those found in RPYS.  
In contrast to RPYS, PCS contains an additional normalization step. Specifically, the de-
trending function discussed thus far only considers the aggregated cited reference activity over 
time. This can be problematic for finding seminal works as a very high “peak” of an RPYS de-
trending function could be due to either a large surge in the influence of a single document (i.e., 
a seminal work) or due to the influence of multiple documents in a given year. To help us isolate 
the former cases, we extend the de-trending procedure as follows: 
 𝑃𝐶𝑆(𝑡) = 𝑓(𝑡) ∙
 Count of References to Most Referenced Patent in Year 𝑡 
𝐶𝑡
 (2) 
Thus, by Equation 1 years with abnormally high numbers of references are identified, and by 
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Equation 2 the values from Equation 1 are reduced based on the percentage of all references 
from that year coming from the most referenced patent.  
PCS Application  
Figure 1 shows the web-application implementing the PCS analysis for open use (hosted 
at www.leydesdorff.net/pcs). The application takes from the user a keyword (e.g., RNAi) or 
phrase query (e.g., “interference RNA”). Searches can be combined by the OR operator through 
the inclusion of commas (e.g., RNAi,“interference RNA”, siRNA, “RNA interference”). Once a 
user clicks the Search button (Fig. 1, upper left), a GET request is sent to the PatentsView API 
(see Methods for details) to return metadata on any granted US patents containing those 
keywords or phrases in the title or abstract. The returned metadata arrives in the form 
Javascript Object Notation (json) with the relevant fields for conducting PCS (e.g., cited patents, 
cited patents’ granted dates). Data is visualized using the HighCharts JavaScript library, which 
is free to use for non-commercial purposes. 
The application provides two pieces of summary data (Fig. 1, upper right). The first is the 
number of granted US patents in the PatentsView database that were returned from the user’s 
search. The second is the number of unique patents referenced by the cohort of patents from 
the search results.  
The main output of the PCS tool is the reference spectrum of these returned patents revealing 
the backward citation distribution. Within the plot, two visualizations are rendered. The first is 
the raw count of backward citations arranged by the granted year of the references (Fig. 1, left). 
This is represented via a bar graph corresponding to the left y-axis. The second is a smoothed 
lline of the normalized score of backward citations arranged by the granted year of the 
references. This graph aligns with the right y-axis (Fig. 1, right).  
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The visualization is interactive, allowing users to explore results. Specifically, when the user’s 
mouse hovers over data corresponding to a given reference granted year, a tooltip provides the 
value of both the left and right y-axis. In addition, clicking on any reference year will redirect the 
user to the full patent document corresponding to the most referenced patent granted that year. 
Finally, the system determines which referenced patent has the highest positive value in its 
normalized citation score and tells the user in plain text that this is the tool’s estimation of the 
most impactful historical patent for the corresponding search (Fig. 1, bottom). 
 
Figure 1. Image of the PCS web-application. In this demo, the user queried patents containing either the 
key terms “RNAi” or “siRNA” or the phrases “interference RNA” or “RNA interference.” The system then 
searched the titles and abstracts of US patents within the PatentsView database for these search terms. 
The result was 1,217 granted US patents containing 4,065 unique patent references. The patent 
references were analyzed via PCS to produce a visualization of the spectrum of impactful historical patent 
references. PCS identified the most important historical patent for this field: US6506559 – Genetic 
inhibition by double-stranded RNA by Fire et al.  (2003), a finding that converges with independent 
reports from subject matter experts (Schmidt et al., 2007).  
Results 
Case Study 1: RNAi, an emerging technology area 
To demonstrate the utility of this tool, we applied PCS to an area of biomedical innovation: RNA 
interference. We selected RNA interference (hereto RNAi) as a use case for two reasons: (1) 
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RNAi represents a burgeoning domain of biomedical innovation with potential therapeutic 
applications for the treatment of viral infections and cancer; and (2) the patent landscape of 
RNAi has been studied by subject matter experts, which allows us to compare the results of 
PCS with their conclusions (Schmidt, 2007).   
 
Figure 2. PCS plot for RNAi. The analysis identified the single most impactful patent in this area of 
innovation to be US6506559 by Fire et al granted in 2003, converging with the opinion of a subject matter 
expert. The odds of correctly identifying this patent by chance were 0.00025. 
In conducting our analysis on RNAi, we chose as our search query terms that were previously 
used to explore RNAi from a scientometric perspective (Leydesdorff & Rafols, 2011; Rotolo et 
al., 2017). Specifically, we input either the strings siRNA or RNAi or interference RNA or RNA 
interference and the tool searched for US patents containing these terms in the title or abstract. 
As of FEB2017, this search yields 1,218 granted US patents possessing 4,065 unique patent 
references. Given the number of references analyzed, the odds of correctly guessing the key 
seminal patent by chance are 1 out of 4,065, or 0.00025. Conducting PCS on this search string, 
the tool produced US6506559 – Genetic inhibition by double-stranded DNA by Andrew Fire and 
colleagues, which was granted in 2003, as its estimate of the most seminal patent. The patent, 
commonly referred to as the Carnegie patent for the assignee organization, is clearly described 
as the foundational patent for RNAi (Schmidt, 2007). The binomial test of selecting the 
foundational patent reference correctly on the first attempt is significant (P = 0.0005).  
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We note that if running this analysis without the addition of our new normalization procedure, 
the highest peak would be attributed to 2009 (based on the traditional RPYS process). To users, 
this would suggest the most significant historical patent for RNAi occurred in 2009 and likely 
attributable to that year’s most cited work, a patent by Leake et al (US7595387). However, this 
result would be inconsistent with the foundational patent identified by subject matter experts and 
shows that the absence of this new normalization procedure makes it more difficult for the user 
to veridically ascertain the most seminal patent in a field.  
Without the new normalization procedure, peak height in the resulting graph is not influenced by 
the impact of a given year’s most referenced work. Our results, on the other hand, highlight the 
value of the new normalization procedure of PCS, which appropriately shifts the highest peak 
from 2009 to 2003 due to the large share of cited references in 2003 pointing to the patent by 
Fire et al. The new normalization procedure thereby simplifies the task of identifying the most 
seminal patent in the field of RNAi for the user. 
In addition to correctly specifying the foundational patent for RNAi, the PCS application 
identified several other patent references of interest (as shown by peaks in the graph). Of 
particular note, the peak observed in 2006 corresponds to US7056704 – RNA interference 
mediating small RNA molecules by Thomas Tuschl and colleagues. Schmidt (2007) includes 
this patent amongst the most seminal in the RNAi field as it details siRNA architectures thought 
to be critical drug efficacy.  
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Figure 3. PCS plot for cholesterol. The patent identified as most seminal in this area was US4681893 by 
Bruce Roth granted in 1987. This represents the fundamental patent underlying the medication 
Atorvastatin (ie., Lipitor).  
Casse Study 2: Cholesterol, a broad area of biomedical importance 
In our second case study, we opted to conduct PCS on a broad area of biomedical relevance. 
Thus, for this case, we searched for the term cholesterol with the aim of uncovering the seminal 
patent pertaining to cholesterol therapies or measurement. The PCS method identified 
US4681893, granted in 1987, as the most seminal patent. This patent, produced by Bruce Roth 
at the Warner-Lambert Company, is the foundational intellectual property underlying 
Atorvastatin (Hutchins, 2003). Otherwise known as Lipitor, this technology has played a 
tremendous role in preventing cardiovascular disease. Though it expired in 2009, this patent 
played a transformative role for biomedical innovations dealing with cholesterol. Also of note in 
the PCS plot are a pair of peaks corresponding to patents US8030457 granted in 2011 and 
US8563698 granted in 2013, both by Simon Jackson and colleagues. These patents are central 
to the production of evolocumab. More commonly known by the brand name Repatha, 
evolocumab is an antibody that is used to treat hypercholesterolemia (Markham, 2015).  
Discussion 
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Identifying intellectual pathways within biomedical science and technology is an important 
component of patent landscapes required by businesses and policy-makers. The rapid 
identification of landmark patents by PCS will support the generation of data-driven patent 
landscapes. Using the PCS methodology and application described here, it will be easier for 
decision-makers to understand the fundamental patents of myriad biotechnologies as well as 
the companies (assignees) and people (inventors) responsible for them.  
To demonstrate the effectiveness of PCS, we applied the application to two distinct use-cases. 
The first is for RNA interference, an emerging technology area with the potential for new 
therapeutic interventions. Compared with prior subject matter expert reports on RNAi patents 
(Schmidt, 2007), PCS correctly identified the foundational patent by Andrew Fire et al (2003). 
Notably, lead authors Andrew Fire and Craig Mello on this seminal patent were both awarded 
the Nobel Prize for their research on RNAi. Our second case study focused on cholesterol, a 
broader topic area of biomedical relevance. For this area, PCS identified the patents underlying 
Lipitor and Repatha, two critical biomedical therapies for maintaining healthy levels of 
cholesterol. In short, PCS provides research policy makers, life scientists and scientometricians 
broader access to a tool capable of identifying the important historical influences in areas of 
innovation. 
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